Inhibitor of the STAT3 signaling pathway; inhibits the activation, nuclear translocation and transactivation of STAT3. Displays selectivity for STAT3 over STAT1, STAT5, JAK1, JAK2 and Src kinases. Inhibits the transcription of STAT3 target genes and induces cell growth inhibition, apoptosis and cell cycle arrest of cancer cells with constitutively active STAT3. Also reversibly inhibits mTORC1 signaling and stimulates autophagy in vitro
; displays antineoplastic effects in acute myelogenous leukemia (AML) stem cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.
Balgi et al.
PLoS One, 2009;4:e7124
Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-κB pathway and generation of reactive oxygen species.
Jin et al.
Cancer Res., 2010;70:2516
Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway.
Ren et al.
ACS Med.Chem.Lett., 2010;1:454
The citations listed below are publications that use Tocris products. Selected citations for Niclosamide include:
Showing Results 1 - 1 of 1